Dr. Cassidy and colleagues pooled results from 6 studies and compared outcomes among 3074 patients who received 5-fluorouracil-containing therapies with ...
... 72 percent of patients in the XELOX group did not experience disease progression after three years versus 69 percent of those in the 5-FU/LV group. ...
Researchers said that picoplatin combined with 5-fluorouracil and leucovorin demonstrated a statistically significant reduction of neurotoxicity when ...
... of intravenous picoplatin in combination with 5-fluorouracil and leucovorin (the FOLPI regimen) to oxaliplatin given in combination with 5-fluorouracil...
One of the studies examined the use of second-line panitumumab 6 mg/kg plus FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) compared with FOLFIRI alone ...
... lived longer after surgery without their tumors progressing than those who received an older regimen, the drugs 5-fluorouracil (5-FU) and leucovorin. ...
Email this story